Cargando…

Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant

Aquatic microbes produce diverse secondary metabolites with interesting biological activities. Cytotoxic metabolites have the potential to become lead compounds or drugs for cancer treatment. Many cytotoxic compounds, however, show undesirable toxicity at higher concentrations. Such undesirable acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wahome, Paul G., Beauchesne, Kevin R., Pedone, Anna C., Cavanagh, John, Melander, Christian, Zimba, Paul, Moeller, Peter D. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306925/
https://www.ncbi.nlm.nih.gov/pubmed/25548974
http://dx.doi.org/10.3390/md13010065
_version_ 1782354386012340224
author Wahome, Paul G.
Beauchesne, Kevin R.
Pedone, Anna C.
Cavanagh, John
Melander, Christian
Zimba, Paul
Moeller, Peter D. R.
author_facet Wahome, Paul G.
Beauchesne, Kevin R.
Pedone, Anna C.
Cavanagh, John
Melander, Christian
Zimba, Paul
Moeller, Peter D. R.
author_sort Wahome, Paul G.
collection PubMed
description Aquatic microbes produce diverse secondary metabolites with interesting biological activities. Cytotoxic metabolites have the potential to become lead compounds or drugs for cancer treatment. Many cytotoxic compounds, however, show undesirable toxicity at higher concentrations. Such undesirable activity may be reduced or eliminated by using lower doses of the cytotoxic compound in combination with another compound that modulates its activity. Here, we have examined the cytotoxicity of four microbial metabolites [ethyl N-(2-phenethyl) carbamate (NP-1), Euglenophycin, Anabaenopeptin, and Glycolipid 652] using three in vitro cell lines [human breast cancer cells (MCF-7), mouse neuroblastoma cells (N2a), and rat pituitary epithelial cells (GH4C1)]. The compounds showed variable cytotoxicity, with Euglenophycin displaying specificity for N2a cells. We have also examined the modulatory power of NP-1 on the cytotoxicity of the other three compounds and found that at a permissible concentration (125 µg/mL), NP-1 sensitized N2a and MCF-7 cells to Euglenophycin and Glycolipid 652 induced cytotoxicity.
format Online
Article
Text
id pubmed-4306925
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-43069252015-02-02 Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant Wahome, Paul G. Beauchesne, Kevin R. Pedone, Anna C. Cavanagh, John Melander, Christian Zimba, Paul Moeller, Peter D. R. Mar Drugs Communication Aquatic microbes produce diverse secondary metabolites with interesting biological activities. Cytotoxic metabolites have the potential to become lead compounds or drugs for cancer treatment. Many cytotoxic compounds, however, show undesirable toxicity at higher concentrations. Such undesirable activity may be reduced or eliminated by using lower doses of the cytotoxic compound in combination with another compound that modulates its activity. Here, we have examined the cytotoxicity of four microbial metabolites [ethyl N-(2-phenethyl) carbamate (NP-1), Euglenophycin, Anabaenopeptin, and Glycolipid 652] using three in vitro cell lines [human breast cancer cells (MCF-7), mouse neuroblastoma cells (N2a), and rat pituitary epithelial cells (GH4C1)]. The compounds showed variable cytotoxicity, with Euglenophycin displaying specificity for N2a cells. We have also examined the modulatory power of NP-1 on the cytotoxicity of the other three compounds and found that at a permissible concentration (125 µg/mL), NP-1 sensitized N2a and MCF-7 cells to Euglenophycin and Glycolipid 652 induced cytotoxicity. MDPI 2014-12-26 /pmc/articles/PMC4306925/ /pubmed/25548974 http://dx.doi.org/10.3390/md13010065 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Wahome, Paul G.
Beauchesne, Kevin R.
Pedone, Anna C.
Cavanagh, John
Melander, Christian
Zimba, Paul
Moeller, Peter D. R.
Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant
title Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant
title_full Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant
title_fullStr Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant
title_full_unstemmed Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant
title_short Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant
title_sort augmenting anti-cancer natural products with a small molecule adjuvant
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306925/
https://www.ncbi.nlm.nih.gov/pubmed/25548974
http://dx.doi.org/10.3390/md13010065
work_keys_str_mv AT wahomepaulg augmentinganticancernaturalproductswithasmallmoleculeadjuvant
AT beauchesnekevinr augmentinganticancernaturalproductswithasmallmoleculeadjuvant
AT pedoneannac augmentinganticancernaturalproductswithasmallmoleculeadjuvant
AT cavanaghjohn augmentinganticancernaturalproductswithasmallmoleculeadjuvant
AT melanderchristian augmentinganticancernaturalproductswithasmallmoleculeadjuvant
AT zimbapaul augmentinganticancernaturalproductswithasmallmoleculeadjuvant
AT moellerpeterdr augmentinganticancernaturalproductswithasmallmoleculeadjuvant